SCHEMBL8309525

SCHEMBL8309525

Nc1nc2c(Cl)cc(F)cc2s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.68
LMNA P02545 2/20 0.53
PDE10A Q9Y233 1/20 0.53
AXL P30530 1/20 0.49
GFER P55789 1/20 0.49
SMN1; SMN2 Q16637 6/20 0.44
HSD17B10 Q99714 2/20 0.44
NSD1 Q96L73 2/20 0.42
RAB9A P51151 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
PDPK1 O15530 1/20 0.37
CYP3A4 P08684 2/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
NSD2 O96028 1/20 0.35
NSD3 Q9BZ95 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8331402 0.81 ALDH1A1 (0.43) ALDH1A1LMNAPDE10AAXLGFER
SCHEMBL474219 0.81 ALDH1A1 (0.61) ALDH1A1LMNAAXLGFERSMN1; SMN2
SCHEMBL7776276 0.81 ALDH1A1 (0.72) ALDH1A1LMNAPDE10AGFERSMN1; SMN2
SCHEMBL6718517 0.81 ALDH1A1 (1.00) ALDH1A1LMNAPDE10ASMN1; SMN2HSD17B10
SCHEMBL8311475 0.79 ALDH1A1 (0.42) ALDH1A1LMNAPDE10AAXLGFER
SCHEMBL22253414 0.78 ALDH1A1 (0.68) ALDH1A1LMNAPDE10ASMN1; SMN2HSD17B10
SCHEMBL16049076 0.78 ALDH1A1 (0.53) ALDH1A1LMNAPDE10AAXLGFER
SCHEMBL21976406 0.78 HSD17B10 (0.68) ALDH1A1LMNAPDE10AAXLGFER
SCHEMBL8330380 0.78 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2HSD17B10RAB9ATDP1
SCHEMBL2316142 0.78 ALDH1A1 (0.68) ALDH1A1LMNAPDE10AAXLGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3697860-A2 SURFACE TREATMENT Interphase Materials Inc. (US) 2020-08-26 EP claimed
US-20200231842-A1 Surface Treatment INTERPHASE MAT INC (US) 2020-07-23 US claimed
WO-2019164546-A2 SURFACE TREATMENT INTERPHASE MATERIALS INC. (US) 2019-08-29 WO claimed
US-20250075101-A1 SURFACE TREATMENT Interphase Materials, Inc (US) 2025-03-06 US disclosed
US-12146071-B2 Surface treatment INTERPHASE MATERIALS INC. (US) 2024-11-19 US disclosed
WO-2024233501-A2 THERAPEUTIC COMPOUNDS ALLOROCK, INC. (US) 2024-11-14 WO disclosed
US-11958847-B1 Pyrazolidinedione derivatives and their use as PPAR-gamma inhibitors King Faisal University (SA) 2024-04-16 US disclosed
US-11845743-B1 Pyrazolidinedione derivatives and their use as PPAR-gamma inhibitors King Faisal University (SA) 2023-12-19 US disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
EP-3697860-A2 SURFACE TREATMENT Interphase Materials Inc. (US) 2020-08-26 EP disclosed
US-20200231842-A1 Surface Treatment INTERPHASE MAT INC (US) 2020-07-23 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2019164546-A2 SURFACE TREATMENT INTERPHASE MATERIALS INC. (US) 2019-08-29 WO disclosed
EP-0958295-A1 SUBSTITUTED 2-(2,4(1H,3H)-PYRIMIDINDION-3-YL) BENZTHIAZOLES BASF AKTIENGESELLSCHAFT (DE) 1999-11-24 EP disclosed
US-5888940-A DESICCATING PLANTS BASF AKTIENGESELLSCHAFT (DE) 1999-03-30 US disclosed
CN-1194645-A Substituted benzothiazols with herbicidal action BASF AG (DE) 1998-09-30 CN disclosed
EP-0862569-A1 SUBSTITUTED BENZOTHIAZOLS WITH HERBICIDAL ACTION BASF AKTIENGESELLSCHAFT (DE) 1998-09-09 EP disclosed
WO-1998033796-A1 SUBSTITUTED 2-(2,4(1H,3H)-PYRIMIDINDION-3-YL) BENZTHIAZOLES BASF AKTIENGESELLSCHAFT (DE) 1998-08-06 WO disclosed
WO-1997008171-A1 SUBSTITUTED BENZOTHIAZOLS WITH HERBICIDAL ACTION BASF AKTIENGESELLSCHAFT (DE) 1997-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 ALDH1A1 1618/4885LMNA 745/4885PDE10A 1981/4885
US-11845743-B1 Pyrazolidinedione derivatives and their use as PPAR-gamma inhibitors PPARD, PPARG, PPARA ALDH1A1 1424/4885LMNA 2916/4885PDE10A 1880/4885
US-11958847-B1 Pyrazolidinedione derivatives and their use as PPAR-gamma inhibitors PPARD, PPARG, PPARA ALDH1A1 1424/4885LMNA 2916/4885PDE10A 1880/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 ALDH1A1 1598/4885LMNA 603/4885PDE10A 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.